TY - JOUR
T1 - Pulmonary toxicity and gene expression changes after short-term inhalation exposure to surface-modified copper oxide nanoparticles
AU - Gosens, Ilse
AU - Costa, Pedro M.
AU - Olsson, Magnus
AU - Stone, Vicki
AU - Costa, Anna L.
AU - Brunelli, Andrea
AU - Badetti, Elena
AU - Bonetto, Alessandro
AU - Bokkers, Bas G. H.
AU - de Jong, Wim H.
AU - Williams, Andrew
AU - Halappanavar, Sabina
AU - Fadeel, Bengt
AU - Cassee, Flemming R.
N1 - Funding Information:
This work was supported by the SUN (?sustainable nanotechnology?) project funded by the Seventh Framework Program of the European Commission (grant agreement no. 604305), and by the RIVM Strategic Research Program, the Netherlands (SPR, E/121504). P.M.C. acknowledges the support provided by national funds to UCIBIO through Funda??o para a Ci?ncia e Tecnologia (FCT, Portugal), ref. UIDB/04378/2020. S.H. acknowledges the support of the Health Canada Genomics Research and Development Initiative. The authors thank M. V. W. Wijnands, for the histopathological examinations, and E.H.J.M. Jansen, D.L.A.C. Leseman, C.M.R. Soputan, J. Rigters, S. Oude Hendrikman, P. K. Beekhof, B. Nagarajah, L.J.J. de la Fonteyne, T. Schouten, A. Gomersbach, H. Verharen, H.J. Heusinkveld, A.J.F. Boere, and P.H.B. Fokkens, all at RIVM, for their help with the animal experiments and for valuable technical assistance. The authors also thank D. Wu at Health Canada for assistance with the microarray analysis, and S. Ortelli for the thermographic analysis of the modified CuO NPs.
Funding Information:
This work was supported by the SUN (‘sustainable nanotechnology’) project funded by the Seventh Framework Program of the European Commission (grant agreement no. 604305 ), and by the RIVM Strategic Research Program , the Netherlands (SPR, E/121504 ). P.M.C. acknowledges the support provided by national funds to UCIBIO through Fundação para a Ciência e Tecnologia (FCT, Portugal), ref. UIDB/04378/2020. S.H. acknowledges the support of the Health Canada Genomics Research and Development Initiative. The authors thank M. V. W. Wijnands, for the histopathological examinations, and E.H.J.M. Jansen, D.L.A.C. Leseman, C.M.R. Soputan, J. Rigters, S. Oude Hendrikman, P. K. Beekhof, B. Nagarajah, L.J.J. de la Fonteyne, T. Schouten, A. Gomersbach, H. Verharen, H.J. Heusinkveld, A.J.F. Boere, and P.H.B. Fokkens, all at RIVM, for their help with the animal experiments and for valuable technical assistance. The authors also thank D. Wu at Health Canada for assistance with the microarray analysis, and S. Ortelli for the thermographic analysis of the modified CuO NPs.
Publisher Copyright:
© 2021 The Authors
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Copper oxide nanoparticles (CuO NPs) have previously been shown to cause dose-dependent pulmonary toxicity following inhalation. Here, CuO NPs (10 nm), coated with polyethylenimine (PEI) or ascorbate (ASC) resulting in positively or negatively charged NPs, respectively, were evaluated. Rats were exposed nose-only to similar exposure dose levels of ASC or PEI coated CuO NPs for 5 consecutive days. On day 6 and day 27 post-exposure, pulmonary toxicity markers in bronchoalveolar lavage fluid (BALF), lung histopathology and genome-wide transcriptomic changes in lungs, were assessed. BALF analyses showed a dose-dependent pulmonary inflammation and cell damage, which was supported by the lung histopathological findings of hypertrophy/hyperplasia of bronchiolar and alveolar epithelium, interstitial and alveolar inflammation, and paracortical histiocytosis in mediastinal lymph nodes for both types of CuO NPs. Transcriptomics analysis showed that pathways related to inflammation and cell proliferation were significantly activated. Additionally, we found evidence for the dysregulation of drug metabolism-related genes, especially in rats exposed to ASC-coated CuO NPs. Overall, no differences in the type of toxic effects and potency between the two surface coatings could be established, except with respect to the (regional) dose that initiates bronchiolar and alveolar hypertrophy. This disproves our hypothesis that differences in surface coatings affect the pulmonary toxicity of CuO NPs.
AB - Copper oxide nanoparticles (CuO NPs) have previously been shown to cause dose-dependent pulmonary toxicity following inhalation. Here, CuO NPs (10 nm), coated with polyethylenimine (PEI) or ascorbate (ASC) resulting in positively or negatively charged NPs, respectively, were evaluated. Rats were exposed nose-only to similar exposure dose levels of ASC or PEI coated CuO NPs for 5 consecutive days. On day 6 and day 27 post-exposure, pulmonary toxicity markers in bronchoalveolar lavage fluid (BALF), lung histopathology and genome-wide transcriptomic changes in lungs, were assessed. BALF analyses showed a dose-dependent pulmonary inflammation and cell damage, which was supported by the lung histopathological findings of hypertrophy/hyperplasia of bronchiolar and alveolar epithelium, interstitial and alveolar inflammation, and paracortical histiocytosis in mediastinal lymph nodes for both types of CuO NPs. Transcriptomics analysis showed that pathways related to inflammation and cell proliferation were significantly activated. Additionally, we found evidence for the dysregulation of drug metabolism-related genes, especially in rats exposed to ASC-coated CuO NPs. Overall, no differences in the type of toxic effects and potency between the two surface coatings could be established, except with respect to the (regional) dose that initiates bronchiolar and alveolar hypertrophy. This disproves our hypothesis that differences in surface coatings affect the pulmonary toxicity of CuO NPs.
KW - Copper oxide
KW - Nanoparticles
KW - Pulmonary toxicity
KW - Safe-by-design
KW - Transcriptomics
UR - http://www.scopus.com/inward/record.url?scp=85103423419&partnerID=8YFLogxK
U2 - 10.1016/j.impact.2021.100313
DO - 10.1016/j.impact.2021.100313
M3 - Article
C2 - 35559970
SN - 2452-0748
VL - 22
JO - NanoImpact
JF - NanoImpact
M1 - 100313
ER -